Drug Profile
LM 030
Alternative Names: BPR 277; LM-030Latest Information Update: 19 May 2023
Price :
$50
*
At a glance
- Originator Novartis
- Developer LifeMax Laboratories; Novartis
- Class Skin disorder therapies
- Mechanism of Action Kallikrein-related peptidase inhibitors; Pancreatic elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Netherton Syndrome
- No development reported Atopic dermatitis
Most Recent Events
- 19 May 2023 Chemical structure information added
- 25 Jan 2023 Phase-II/III clinical development is ongoing in Netherton Syndrome, in Undisclosed location (Topical) (LifeMax Laboratories pipeline, January 2023)
- 23 Jul 2022 No development reported - Phase-II/III for Netherton-Syndrome (Topical)